Clinical characteristics of patients with diffuse large B-cell lymphoma
| . | DLBCL patients with BCL-6 more than 1.3 . | DLBCL patients with BCL-6 equal to or lower than 1.3 . | All DLBCL patients . |
|---|---|---|---|
| No. patients | |||
| Age (y) | 43 | 18 | 61 |
| Median (range) | 49 (21-78) | 45 (18-73) | 50 (18-78) |
| Clinical stage3-150 | |||
| 1 | 3 | 4 | 7 |
| 2 | 15 | 8 | 23 |
| 3 | 5 | 0 | 5 |
| 4 | 19 | 5 | 24 |
| Performance status3-150 | |||
| 0-1 | 35 | 16 | 51 |
| At least 2 | 5 | 1 | 6 |
| B symptoms3-150 | |||
| Yes | 10 | 4 | 14 |
| No | 32 | 13 | 45 |
| LDH3-150 | |||
| High | 19 | 9 | 28 |
| Low | 19 | 8 | 27 |
| DLBCL origin | |||
| Nodal | 26 | 13 | 39 |
| Extranodal | 17 | 5 | 22 |
| IPI3-150 | |||
| 0-2 | 28 | 13 | 41 |
| 3-5 | 10 | 4 | 14 |
| . | DLBCL patients with BCL-6 more than 1.3 . | DLBCL patients with BCL-6 equal to or lower than 1.3 . | All DLBCL patients . |
|---|---|---|---|
| No. patients | |||
| Age (y) | 43 | 18 | 61 |
| Median (range) | 49 (21-78) | 45 (18-73) | 50 (18-78) |
| Clinical stage3-150 | |||
| 1 | 3 | 4 | 7 |
| 2 | 15 | 8 | 23 |
| 3 | 5 | 0 | 5 |
| 4 | 19 | 5 | 24 |
| Performance status3-150 | |||
| 0-1 | 35 | 16 | 51 |
| At least 2 | 5 | 1 | 6 |
| B symptoms3-150 | |||
| Yes | 10 | 4 | 14 |
| No | 32 | 13 | 45 |
| LDH3-150 | |||
| High | 19 | 9 | 28 |
| Low | 19 | 8 | 27 |
| DLBCL origin | |||
| Nodal | 26 | 13 | 39 |
| Extranodal | 17 | 5 | 22 |
| IPI3-150 | |||
| 0-2 | 28 | 13 | 41 |
| 3-5 | 10 | 4 | 14 |
DLBCL indicates diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; IPI, International Prognostic Index.
Data were missing for some of the studied patients with DLBCL.